Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-1

+ Details

Name:	us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479668/805-30-25-6

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 35
-Paragraph 1
-Subparagraph (b)
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479613/805-30-35-1

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business acquisition number of specified clinical milestones achieved.

+ References

No definition available.

+ Details

Name:	vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved
Namespace Prefix:	vir_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Business combinations additional consideration payable upon achievement of specified events.

+ References

No definition available.

+ Details

Name:	vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Regulatory milestones achieved during the reporting period.

+ References

No definition available.

+ Details

Name:	vir_RegulatoryMilestonesAchieved
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Sales milestones achieved during the reporting period

+ References

No definition available.

+ Details

Name:	vir_SalesMilestonesAchieved
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Specified clinical development milestones payment.

+ References

No definition available.

+ Details

Name:	vir_SpecifiedClinicalDevelopmentMilestonesPayment
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=vir_HepatitisBVirusProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=vir_AnotherProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions - Additional Information (Details) - Humabs $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($) Milestone	Dec. 31, 2022 USD ($)	Aug. 31, 2017 USD ($)
Business Acquisition [Line Items]
Contingent consideration recognized	$ 26.0			$ 23.4
Developed Technologies \| Minimum
Business Acquisition [Line Items]
Estimated remaining useful lives	7 years
Developed Technologies \| Maximum
Business Acquisition [Line Items]
Estimated remaining useful lives	12 years
HBV product
Business Acquisition [Line Items]
Additional consideration payable upon achievement of specified milestone events					$ 135.0
Specified clinical development milestones payment			$ 20.0
Another Product
Business Acquisition [Line Items]
Additional consideration payable upon achievement of specified milestone events					$ 105.0
SARS-CoV-2 Product
Business Acquisition [Line Items]
Number of specified clinical milestones achieved \| Milestone			2
Specified clinical development milestones payment			$ 20.0
Regulatory milestones achieved		$ 35.0
Sales milestone achieved		$ 60.0